Investors may be asking whether Moderna's current share price reflects its underlying worth, or if the market is mispricing ...

European Medicines Agency approves Moderna's mRNA flu vaccine with strong efficacy in older adults. US FDA initially declines ...

Broader biotech positioning aligns with movements tracked across the nasdaq ecosystem.

Moderna's full pipeline may fuel long-term growth.

COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver ...

They aren't just "pandemic stocks." ...

By Bhanvi Satija LONDON, April 1 (Reuters) - Vaccine makers Pfizer and BioNTech halted a large U.S. trial of their updated ...

Continue » Moderna's shares could soar as it advances its mRNA platform. Compared to older vaccines, those of the mRNA ...

A European panel has backed expanding the RSV vaccine from adults aged 60 years or older to all adults aged 18 years or older ...

The Food and Drug Administration has declined to review Moderna’s application for the first mRNA-based flu vaccine, a decision that shocked the company and that comes as the agency plans to tighten ...

Moderna (MRNA) ended the recent trading session at $49.56, demonstrating a -7.49% change from the preceding day's closing ...